Whenever companies announce a deal, managements try to paint it as a great move for each shareholder group. Experience says that is rarely the case, but Teva Pharmaceuticals' (Nasdaq:TEVA) acquisition of Cephalon (Nasdaq:CEPH) really could be a case where that is true. This deal solves significant, but different, problems for each company.

Tutorial: Mergers And Acquisitions 101

The Terms Of The Deal
Unlike Valeant's (NYSE:VRX) attempt at a hostile bid (or its thus far unsuccessful attempt to find a friendly agreement with Cephalon's board), Teva pursued a friendly offer and both boards agreed to it unanimously. Teva will acquire Cephalon in an all-cash deal that pays Cephalon shareholders $81.50 - 12% more than what Valeant had offered. The deal amounts to about $6.8 billion for Teva, which will have to raise debt for the bid.

Not Great, But Better
Cephalon shareholders may still grumble at the terms of the deal. After all, less than six times trailing EBITDA and about two times trailing revenue is not an exciting premium. What's more, in recent memory Pfizer (NYSE:PFE) paid for more for King and Abbott (NYSE:ABT) paid for Kos.

Still, Cephalon shareholders should realize that this was about as good a deal as they could have hoped for in a buyout. The company has some promise with Nuvigil, Fentora, and Treanda, but there just is not enough in the pipeline to really make for a lot of excitement or a rich valuation. Frustrating as it may be, this deal basically maximizes the value Cephalon had as a going concern with none of the ongoing execution risk. (For more, see Mergers And Acquisitions: Understanding Takeovers.)

A Smart Move for Teva
With recent news from Biogen Idec (Nasdaq:BIIB) casting doubt on Teva's long-term prospects in the multiple sclerosis franchise, and a dearth of major patent expirations after 2013, Teva needed to do something to change up its business. The acquisition of Cephalon will give Teva more than 20 branded drugs, less risk on the MS front (since that will be a smaller part of the business) and an interesting generics business within Cephalon (Mepha, acquired by Cephalon about a year ago). What's more, it should be accretive more or less immediately.

A New Teva?
It will be interesting to see where Teva goes in the next few years. Major pharmaceutical companies like Novartis (NYSE:NVS) and Sanofi-Aventis (NYSE:SNY) have expanded into generics as a way of adding a little more predictability to the business models and better leveraging the sales infrastructure.

Will Teva now try to bulk up its branded business even further, to take advantage of the growth and margins present there, and/or find a value-accreting use of cash? It is a risky move, but the fact remains that reimbursement for branded drugs is still very strong, and there are rich rewards to developing successful compounds.

The real question may be how much more Teva will pay for its expansion plans. Teva trades at a premium to many pharmaceutical companies, and that could make its shares useful as a currency. That said, recent deals have been cash-and-carry, so Teva may find its options more limited on that basis. (For more, see Pharmaceutical Phenoms: America's Best Selling Medicines.)

The Bottom Line
Teva is a borderline buy candidate. There is definitely value here, and this Cephalon deal improves the company's prospects. There are other, cheaper, ideas out there for investors to consider, but Teva is definitely worthy of consideration. (For more, see Teva's Rocky Road.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  2. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  3. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  4. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  5. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  6. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  7. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  8. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  9. Stock Analysis

    The Biggest Risks of Investing in Netflix Stock

    Examine the current state of Netflix Inc., and learn about three of the major fundamental risks that the company is currently facing.
  10. Stock Analysis

    What Seagate Gains by Acquiring Dot Hill Systems

    Examine the Seagate acquisition of Dot Hill Systems, and learn what Seagate is looking to gain by acquiring Dot Hill's software technology.
  1. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  2. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>
  3. How do I use discounted cash flow (DCF) to value stock?

    Discounted cash flow (DCF) analysis can be a very helpful tool for analysts and investors in equity valuation. It provides ... Read Full Answer >>
  4. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  5. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  6. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!